Suchergebnisse - "Lorusso, Vito"

PubPharm (24)

1

Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients : A machine learning approach

enthalten in: Cancer medicine | 2023

von Fanizzi, A. | Latorre, A. | Bavaro, D. | +12

2

Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer

enthalten in: Scientific reports | 2023

von Fanizzi, A. | Pomarico, D. | Rizzo, A. | +13

3

Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs

enthalten in: Scientific reports | 2021

von Comes, M. | Fanizzi, A. | Bove, S. | +12

4

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

enthalten in: Scientific reports | 2021

von Pizzuti, L. | Barba, M. | Mazzotta, M. | +53

5

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

enthalten in: Journal of cellular physiology | 2020

von Krasniqi, E. | Pizzuti, L. | Barchiesi, G. | +65

6

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer : A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Orlando, L. | Lorusso, V. | Giotta, F. | +15

7

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

enthalten in: International journal of cancer | 2020

von Pizzuti, L. | Krasniqi, E. | Barchiesi, G. | +83

8

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer : A real-world experience

enthalten in: Journal of cellular physiology | 2019

von Pizzuti, L. | Giordano, A. | Michelotti, A. | +65

9

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3) : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von De Placido, S. | Gallo, C. | De Laurentiis, M. | +128

CommentIn: Lancet Oncol. 2018 Apr;19(4):431-432. - PMID 29482984

10

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life : Italian clinical practice versus the CLEOPATRA trial results

enthalten in: Breast (Edinburgh, Scotland) | 2018

von De Placido, S. | Giuliano, M. | Schettini, F. | +17